CoChat
Sign Up
Cited by 172Asthma and respiratory diseasesEosinophilic Disorders and SyndromesEosinophilic Esophagitis

Eosinophils in Autoimmune Diseases

Open access
Diny, Nicola L., Rose, Noel R., Čiháková, Daniela·2017·Frontiers in Immunology
DOI 10.3389/fimmu.2017.00484PMC PMC5406413
Open this paper in CoChat — free accountOpen PDF

Abstract

Eosinophils are multifunctional granulocytes that contribute to initiation and modulation of inflammation. Their role in asthma and parasitic infections has long been recognized. Growing evidence now reveals a role for eosinophils in autoimmune diseases. In this review, we summarize the function of eosinophils in inflammatory bowel diseases, neuromyelitis optica, bullous pemphigoid, autoimmune myocarditis, primary biliary cirrhosis, eosinophilic granulomatosis with polyangiitis, and other autoimmune diseases. Clinical studies, eosinophil-targeted therapies, and experimental models have contributed to our understanding of the regulation and function of eosinophils in these diseases. By examining the role of eosinophils in autoimmune diseases of different organs, we can identify common pathogenic mechanisms. These include degranulation of cytotoxic granule proteins, induction of antibody-dependent cell-mediated cytotoxicity, release of proteases degrading extracellular matrix, immune modulation through cytokines, antigen presentation, and prothrombotic functions. The association of eosinophilic diseases with autoimmune diseases is also examined, showing a possible increase in autoimmune diseases in patients with eosinophilic esophagitis, hypereosinophilic syndrome, and non-allergic asthma. Finally, we summarize key future research needs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2017.00484

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Giant cell myocarditis and eosinophilic necrotizing myocarditis are traditionally classified as autoimmune myocarditis due to their strong association with existing autoimmune conditions.

    “Giant cell myocarditis and eosinophilic necrotizing myocarditis are traditionally classified as autoimmune myocarditis due to their strong association with existing autoimmune conditions”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [30]

    The Eosinophilic Myocarditis section says autoimmune processes often play a role in myocarditis and links eosinophilic myocarditis with EGPA. It does not say that giant cell myocarditis or eosinophilic necrotizing myocarditis are traditionally classified as autoimmune because of strong associations with existing autoimmune conditions; it describes giant cell and eosinophilic myocarditis as usually idiopathic. No page number is available in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • Eosinophilic myocarditis leads to advanced heart disorders such as heart failure, fibrosis, and thrombosis.

    “leading to advanced heart disorders such as heart failure, fibrosis, and thrombosis.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [30]

    The Eosinophilic Myocarditis section (page not provided) describes thrombosis and eventual endomyocardial fibrosis in hypereosinophilic syndrome. It also links myocarditis to dilated cardiomyopathy and heart failure, but says the rate at which patients with eosinophilic myocarditis progress to cardiomyopathy is unknown. The claim presents these outcomes more categorically than the source does. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • Various conditions including infections, drugs, hypersensitivity, and autoimmune factors may be associated with the onset and progress of eosinophilic myocarditis.

    “various conditions including infections, drugs, hypersensitivity, and autoimmune factors may be associated with the onset and progress of this disease.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [30]

  • Eosinophilic myocarditis is characterized by predominant infiltration of eosinophils in the myocardium.

    “Eosinophilic myocarditis is characterized by a predominant infiltration of eosinophils in the myocardium”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [30]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 322

  1. [1]Ohashi PS Oehen S Buerki K Pircher H Ohashi CT Odermatt B Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice. Cell (1991) 65(2): 305– 17. 10.1016/0092-8674(91)90164-T 1901764 · DOI
  2. [2]Waldner H Collins M Kuchroo VK. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest (2004) 113: 990– 7. 10.1172/JCI19388 15057305 PMC379316 · DOI
  3. [3]Ichikawa HT Williams LP Segal BM. Activation of APCs through CD40 or toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J Immunol (2002) 169(5): 2781– 7. 10.4049/jimmunol.169.5.2781 12193753 · DOI
  4. [4]Huang J Xiao Y Xu A Zhou Z. Neutrophils in type 1 diabetes. J Diabetes Investig (2016) 7(5): 652– 63. 10.1111/jdi.12469 27181374 PMC5009125 · DOI
  5. [5]Fraker C Bayer AL. The expanding role of natural killer cells in type 1 diabetes and immunotherapy. Curr Diab Rep (2016) 16(11): 109. 10.1007/s11892-016-0806-7 27664042 · DOI
  6. [6]Jiao G Wang B NK cell subtypes as regulators of autoimmune liver disease. Gastroenterol Res Pract (2016) 2016: 6903496 10.1155/2016/6903496 27462349 PMC4947642 · DOI
  7. [7]Zhou Z Ding M Huang L Gilkeson G Lang R Jiang W. Toll-like receptor-mediated immune responses in intestinal macrophages; implications for mucosal immunity and autoimmune diseases. Clin Immunol (2016) 173: 81– 6. 10.1016/j.clim.2016.09.005 27620642 PMC5148676 · DOI
  8. [8]Waldner H. The role of innate immune responses in autoimmune disease development. Autoimmun Rev (2009) 8: 400– 4. 10.1016/j.autrev.2008.12.019 19162250 · DOI
  9. [9]Sie C Korn T Dendritic cells in central nervous system autoimmunity. Semin Immunopathol (2017) 39(2): 99– 111. 10.1007/s00281-016-0608-7 27888330 · DOI
  10. [10]Exley MA Tsokos GC Mills KHG Elewaut D Mulhearn B. What rheumatologists need to know about innate lymphocytes. Nat Rev Rheumatol (2016) 12: 658– 68. 10.1038/nrrheum.2016.140 27586381 · DOI
  11. [11]Conti P Kempuraj D. Important role of mast cells in multiple sclerosis. Mult Scler Relat Disord (2016) 5: 77– 80. 10.1016/j.msard.2015.11.005 26856948 · DOI
  12. [12]Lopez AF Begley CG Williamson DJ Warren DJ Vadas MA Sanderson CJ. Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells. J Exp Med (1986) 163: 1085– 99. 10.1084/jem.163.5.1085 3486243 PMC2188112 · DOI
  13. [13]Rothenberg ME Pomerantz JL Owen WF Avraham S Soberman RJ Austen KF Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor. J Biol Chem (1988) 263: 13901– 8. 2458354
  14. [14]Sanderson CJ Interleukin-5, eosinophils, and disease. Blood (1992) 79: 3101– 9. 1596561
  15. [15]Johnston LK Hsu C-L Krier-Burris RA Chhiba KD Chien KB McKenzie A IL-33 precedes IL-5 in regulating eosinophil commitment and is required for eosinophil homeostasis. J Immunol (2016) 197(9): 3445– 53. 10.4049/jimmunol.1600611 27683753 PMC5101160 · DOI
  16. [16]Collins PD Marleau S Griffiths-Johnson DA Jose PJ Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med (1995) 182: 1169– 74. 10.1084/jem.182.4.1169 7561691 PMC2192289 · DOI
  17. [17]Rothenberg ME Hogan SP. The eosinophil. Annu Rev Immunol (2006) 24: 147– 74. 10.1146/annurev.immunol.24.021605.090720 16551246 · DOI · Paper page
  18. [18]Kovalszki A Weller PF. Eosinophilia. Prim Care (2016) 43(4): 607– 17. 10.1016/j.pop.2016.07.010 27866580 PMC5293177 · DOI
  19. [19]Matthews AN Friend DS Zimmermann N Sarafi MN Luster AD Pearlman E Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci U S A (1998) 95: 6273– 8. 10.1073/pnas.95.11.6273 9600955 PMC27654 · DOI
  20. [20]Zhang J Lathbury LJ Salamonsen LA. Expression of the chemokine eotaxin and its receptor, CCR3, in human endometrium. Biol Reprod (2000) 62: 404– 11. 10.1095/biolreprod62.2.404 10642580 · DOI
  21. [21]Gouon-Evans V Pollard JW Eotaxin is required for eosinophil homing into the stroma of the pubertal and cycling uterus. Endocrinology (2001) 142: 4515– 21. 10.1210/endo.142.10.8459 11564717 · DOI
  22. [22]Pope SM Zimmermann N Stringer KF Karow ML Rothenberg ME. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol (2005) 175: 5341– 50. 10.4049/jimmunol.175.8.5341 16210640 · DOI
  23. [23]Ahrens R Waddell A Seidu L Blanchard C Carey R Forbes E Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol (2008) 181: 7390– 9. 10.4049/jimmunol.181.10.7390 18981162 PMC2728352 · DOI
  24. [24]Diny NL Hou X Barin JG Chen G Talor MV Schaub J Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart. Eur J Immunol (2016) 46: 2749– 60. 10.1002/eji.201646557 27621211 PMC5404278 · DOI · Paper page
  25. [25]Kitaura M Nakajima T Imai T Harada S Combadiere C Tiffany HL Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem (1996) 271: 7725– 30. 10.1074/jbc.271.13.7725 8631813 · DOI
  26. [26]Kitaura M Suzuki N Imai T Takagi S Suzuki R Nakajima T Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J Biol Chem (1999) 274: 27975– 80. 10.1074/jbc.274.39.27975 10488147 · DOI
  27. [27]Patel VP Kreider BL Li Y Li H Leung K Salcedo T Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med (1997) 185: 1163– 72. 10.1084/jem.185.7.1163 9104803 PMC2196270 · DOI
  28. [28]Lee JJ Jacobsen EA Ochkur SI McGarry MP Condjella RM Doyle AD Human versus mouse eosinophils: “that which we call an eosinophil, by any other name would stain as red”. J Allergy Clin Immunol (2012) 130: 572– 84. 10.1016/j.jaci.2012.07.025 22935586 PMC3496419 · DOI
  29. [29]Sallusto F Mackay CR Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science (1997) 277: 2005– 7. 10.1126/science.277.5334.2005 9302298 · DOI · Paper page
  30. [30]Bochner BS. Novel therapies for eosinophilic disorders. Immunol Allergy Clin North Am (2015) 35: 577– 98. 10.1016/j.iac.2015.05.007 26209901 PMC4515571 · DOI
  31. [31]Rosenberg HF Dyer KD Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol (2013) 13: 9– 22. 10.1038/nri3341 23154224 PMC4357492 · DOI
  32. [32]Acharya KR Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem (2014) 289: 17406– 15. 10.1074/jbc.R113.546218 24802755 PMC4067173 · DOI
  33. [33]Butterworth AE Wassom DL Gleich GJ Loegering DA David JR Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein. J Immunol (1979) 122: 221– 9. 570202
  34. [34]Gleich GJ Frigas E Loegering DA Wassom DL Steinmuller D Cytotoxic properties of the eosinophil major basic protein. J Immunol (1979) 123: 2925– 7. 501097
  35. [35]Frigas E Loegering DA Gleich GJ Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab Invest (1980) 42: 35– 43. 7351830
  36. [36]Zheutlin LM Ackerman SJ Gleich GJ Thomas LL. Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol (1984) 133: 2180– 5. 6206154
  37. [37]Piliponsky AM Pickholtz D Gleich GJ Levi-Schaffer F Human eosinophils induce histamine release from antigen-activated rat peritoneal mast cells: a possible role for mast cells in late-phase allergic reactions. J Allergy ClinImmunol (2001) 107: 993– 1000. 10.1067/mai.2001.114656 11398076 · DOI
  38. [38]Jacoby DB Costello RM Fryer AD. Eosinophil recruitment to the airway nerves. J Allergy ClinImmunol (2001) 107: 211– 8. 10.1067/mai.2001.112940 11174183 · DOI
  39. [39]Morgan RK Costello RW Durcan N Kingham PJ Gleich GJ McLean WG Diverse effects of eosinophil cationic granule proteins on IMR-32 nerve cell signaling and survival. Am J Respir Cell Mol Biol (2005) 33: 169– 77. 10.1165/rcmb.2005-0056OC 15860794 · DOI
  40. [40]Rosenberg HF Ackerman SJ Tenen DG. Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. J Exp Med (1989) 170: 163– 76. 10.1084/jem.170.1.163 2473157 PMC2189377 · DOI
  41. [41]Sorrentino S Glitz DG Hamann KJ Loegering DA Checkel JL Gleich GJ Eosinophil-derived neurotoxin and human liver ribonuclease. Identity of structure and linkage of neurotoxicity to nuclease activity. J Biol Chem (1992) 267: 14859– 65. 1634526
  42. [42]Domachowske JB Dyer KD Bonville CA Rosenberg HF Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis (1998) 177: 1458– 64. 10.1086/515322 9607820 · DOI
  43. [43]Yang D Chen Q Rosenberg HF Rybak SM Newton DL Wang ZY Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J Immunol (2004) 173: 6134– 42. 10.4049/jimmunol.173.10.6134 15528350 PMC2847482 · DOI
  44. [44]Lacy P Latif DA Steward M Musat-Marcu S Man SFP Moqbel R. Divergence of mechanisms regulating respiratory burst in blood and sputum eosinophils and neutrophils from atopic subjects. J Immunol (2003) 170: 2670– 9. 10.4049/jimmunol.170.5.2670 12594296 · DOI
  45. [45]Wang J-G Mahmud SA Nguyen J Slungaard A. Thiocyanate-dependent induction of endothelial cell adhesion molecule expression by phagocyte peroxidases: a novel HOSCN-specific oxidant mechanism to amplify inflammation. J Immunol (2006) 177: 8714– 22. 10.4049/jimmunol.177.12.8714 17142773 · DOI
  46. [46]Wang J-G Mahmud SA Thompson JA Geng J-G Key NS Slungaard A The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood (2006) 107: 558– 65. 10.1182/blood-2005-05-2152 16166591 PMC1895611 · DOI
  47. [47]Dvorak AM Estrella P Ishizaka T. Vesicular transport of peroxidase in human eosinophilic myelocytes. Clin Exp Allergy (1994) 24(1): 10– 8. 10.1111/j.1365-2222.1994.tb00910.x 8156439 · DOI
  48. [48]Melo RCN Spencer LA Perez SAC Ghiran I Dvorak AM Weller PF. Human eosinophils secrete preformed, granule-stored interleukin-4 through distinct vesicular compartments. Traffic (2005) 6: 1047– 57. 10.1111/j.1600-0854.2005.00344.x 16190985 PMC2715427 · DOI
  49. [49]Spencer LA Melo RCN Perez SAC Bafford SP Dvorak AM Weller PF. Cytokine receptor-mediated trafficking of preformed IL-4 in eosinophils identifies an innate immune mechanism of cytokine secretion. Proc Natl Acad Sci U S A (2006) 103: 3333– 8. 10.1073/pnas.0508946103 16492782 PMC1413889 · DOI
  50. [50]Fischer E Capron M Prin L Kusnierz JP Kazatchkine MD. Human eosinophils express CR1 and CR3 complement receptors for cleavage fragments of C3. Cell Immunol (1986) 97(2): 297– 306. 10.1016/0008-8749(86)90400-4 3742611 · DOI
  51. [51]Gounni AS Lamkhioued B Ochiai K Tanaka Y Delaporte E Capron A High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature (1994) 367(6459): 183– 6. 10.1038/367183a0 8114916 · DOI
  52. [52]Grangette C Gruart V Ouaissi MA Rizvi F Delespesse G Capron A IgE receptor on human eosinophils (FcERII). Comparison with B cell CD23 and association with an adhesion molecule. J Immunol (1989) 143(11): 3580– 8. 2531185
  53. [53]Hartnell A Kay AB Wardlaw AJ IFN-gamma induces expression of Fc gamma RIII (CD16) on human eosinophils. J Immunol (1992) 148(5): 1471– 8. 1311348
  54. [54]Decot V Woerly G Loyens M Loiseau S Quatannens B Capron M Heterogeneity of expression of IgA receptors by human, mouse, and rat eosinophils. J Immunol (2005) 174(2): 628– 35. 10.4049/jimmunol.174.2.628 15634880 · DOI
  55. [55]Hallam C Pritchard DI Trigg S Eady RP. Rat eosinophil-mediated antibody-dependent cellular cytotoxicity: investigations of the mechanisms of target cell lysis and inhibition by glucocorticoids. Clin Exp Immunol (1982) 48(3): 641– 8. 7116688 PMC1536620
  56. [56]Van Epps DE Bankhurst AD. Human eosinophils: surface receptors and antibody-dependent cytotoxicity. J Lab Clin Med (1978) 91(4): 612– 7. 565384
  57. [57]Parrillo JE Fauci AS Human eosinophils. Purification and cytotoxic capability of eosinophils from patients with the hypereosinophilic syndrome. Blood (1978) 51: 457– 73. 623908
  58. [58]Noguchi H Kephart GM Colby TV Gleich GJ. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol (1992) 140(2): 521– 8. 1739138 PMC1886427
  59. [59]Phipps S Ying S Wangoo A Ong Y-E Levi-Schaffer F Kay AB. The relationship between allergen-induced tissue eosinophilia and markers of repair and remodeling in human atopic skin. J Immunol (2002) 169: 4604– 12. 10.4049/jimmunol.169.8.4604 12370399 · DOI
  60. [60]Birring SS Parker D McKenna S Hargadon B Brightling CE Pavord ID Sputum eosinophilia in idiopathic pulmonary fibrosis. Inflamm Res (2005) 54: 51– 6. 10.1007/s00011-004-1321-x 15750711 · DOI
  61. [61]Corradi D Vaglio A Maestri R Legname V Leonardi G Bartoloni G Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death. Hum Pathol (2004) 35: 1160– 3. 10.1016/j.humpath.2004.05.008 15343520 · DOI
  62. [62]Pincus SH Ramesh KS Wyler DJ. Eosinophils stimulate fibroblast DNA synthesis. Blood (1987) 70(2): 572– 4. 3607289
  63. [63]Kay AB Phipps S Robinson DS. A role for eosinophils in airway remodelling in asthma. Trends Immunol (2004) 25: 477– 82. 10.1016/j.it.2004.07.006 15324740 · DOI
  64. [64]Minshall EM Leung DYM Martin RJ Song YL Cameron L Ernst P Eosinophil-associated TGF-β1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol (1997) 17: 326– 33. 10.1165/ajrcmb.17.3.2733 9308919 · DOI
  65. [65]Hernnäs J Särnstrand B Lindroth P Peterson CG Venge P Malmström A. Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur J Cell Biol (1992) 59: 352– 63. 1493801
  66. [66]Pégorier S Wagner LA Gleich GJ Pretolani M Eosinophil-derived cationic proteins activate the synthesis of remodeling factors by airway epithelial cells. J Immunol (2006) 177: 4861– 9. 10.4049/jimmunol.177.7.4861 16982928 · DOI
  67. [67]Milici AJ Carroll LA Stukenbrok HA Shay AK Gladue RP Showell HJ. Early eosinophil infiltration into the optic nerve of mice with experimental allergic encephalomyelitis. Lab Invest (1998) 78(10): 1239– 44. 9800949
  68. [68]Costello RW Schofield BH Kephart GM Gleich GJ Jacoby DB Fryer AD. Localization of eosinophils to airway nerves and effect on neuronal M2 muscarinic receptor function. Am J Physiol (1997) 273(1 Pt 1): L93– 103. 9252545
  69. [69]Fryer AD Stein LH Nie Z Curtis DE Evans CM Hodgson ST Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest (2006) 116(1): 228– 36. 10.1172/JCI25423 16374515 PMC1319219 · DOI
  70. [70]Smyth CM Akasheh N Woods S Kay E Morgan RK Thornton MA Activated eosinophils in association with enteric nerves in inflammatory bowel disease. PLoS One (2013) 8: e64216. 10.1371/journal.pone.0064216 23717571 PMC3661526 · DOI
  71. [71]Sawatzky DA Kingham PJ Court E Kumaravel B Fryer AD Jacoby DB Eosinophil adhesion to cholinergic nerves via ICAM-1 and VCAM-1 and associated eosinophil degranulation. Am J Physiol Lung Cell Mol Physiol (2002) 282(6): L1279– 88. 10.1152/ajplung.00279.2001 12003784 · DOI
  72. [72]Kingham PJ McLean WG Sawatzky DA Walsh MT Costello RW. Adhesion-dependent interactions between eosinophils and cholinergic nerves. Am J Physiol Lung Cell Mol Physiol (2002) 282(6): L1229– 38. 10.1152/ajplung.00278.2001 12003778 · DOI
  73. [73]Iwamoto I Nakagawa N Yamazaki H Kimura A Tomioka H Yoshida S Mechanism for substance P-induced activation of human neutrophils and eosinophils. Regul Pept (1993) 46(1–2): 228– 30. 10.1016/0167-0115(93)90042-7 7692498 · DOI
  74. [74]Sunohara N Furukawa S Nishio T Mukoyama M Satoyoshi E. Neurotoxicity of human eosinophils towards peripheral nerves. J Neurol Sci (1989) 92(1): 1– 7. 10.1016/0022-510X(89)90170-6 2769301 · DOI
  75. [75]Hogan SP Mishra A Brandt EB Royalty MP Pope SM Zimmermann N A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol (2001) 2(4): 353– 60. 10.1038/86365 11276207 · DOI
  76. [77]Kingham PJ McLean WG Walsh M-T Fryer AD Gleich GJ Costello RW. Effects of eosinophils on nerve cell morphology and development: the role of reactive oxygen species and p38 MAP kinase. Am J Physiol Lung Cell Mol Physiol (2003) 285(4): L915– 24. 10.1152/ajplung.00094.2003 12794004 · DOI
  77. [78]Garland A Necheles J White SR Neeley SP Leff AR Carson SS Activated eosinophils elicit substance P release from cultured dorsal root ganglion neurons. Am J Physiol (1997) 273(5 Pt 1): L1096– 102. 9374740
  78. [79]Elbon CL Jacoby DB Fryer AD. Pretreatment with an antibody to interleukin-5 prevents loss of pulmonary M2 muscarinic receptor function in antigen-challenged guinea pigs. Am J Respir Cell Mol Biol (1995) 12(3): 320– 8. 10.1165/ajrcmb.12.3.7873198 7873198 · DOI
  79. [80]Yousefi S Gold JA Andina N Lee JJ Kelly AM Kozlowski E Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med (2008) 14: 949– 53. 10.1038/nm.1855 18690244 · DOI · Paper page
  80. [81]Simon D Simon HU Yousefi S. Extracellular DNA traps in allergic, infectious, and autoimmune diseases. Allergy (2013) 68: 409– 16. 10.1111/all.12111 23409745 · DOI
  81. [82]Dworski R Simon H-U Hoskins A Yousefi S. Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways. J Allergy Clin Immunol (2011) 127(5): 1260– 6. 10.1016/j.jaci.2010.12.1103 21315435 PMC3085562 · DOI
  82. [83]Simon D Hoesli S Roth N Staedler S Yousefi S Simon H-U. Eosinophil extracellular DNA traps in skin diseases. J Allergy Clin Immunol (2011) 127(1): 194– 9. 10.1016/j.jaci.2010.11.002 21211654 · DOI
  83. [84]Hartman M-L Piliponsky AM Temkin V Levi-Schaffer F. Human peripheral blood eosinophils express stem cell factor. Blood (2001) 97: 1086– 91. 10.1182/blood.V97.4.1086 11159541 · DOI
  84. [85]Piliponsky AM Gleich GJ Bar I Levi-Schaffer F. Effects of eosinophils on mast cells: a new pathway for the perpetuation of allergic inflammation. Mol Immunol (2002) 38: 1369– 72. 10.1016/S0161-5890(02)00090-1 12217410 · DOI
  85. [86]Solomon A Aloe L Pe’er J Frucht-Pery J Bonini S Bonini S Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J Allergy Clin Immunol (1998) 102(3): 454– 60. 10.1016/S0091-6749(98)70135-6 9768588 · DOI
  86. [87]Otani IM Anilkumar AA Newbury RO Bhagat M Beppu LY Dohil R Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol (2013) 131: 1576– 82. 10.1016/j.jaci.2013.02.042 23623266 PMC3699422 · DOI
  87. [88]Lucey DR Nicholson-Weller A Weller PF. Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci U S A (1989) 86(4): 1348– 51. 10.1073/pnas.86.4.1348 2919183 PMC286687 · DOI
  88. [89]MacKenzie JR Mattes J Dent LA Foster PS. Eosinophils promote allergic disease of the lung by regulating CD4(+) Th2 lymphocyte function. J Immunol (2001) 167(6): 3146– 55. 10.4049/jimmunol.167.6.3146 11544300 · DOI
  89. [90]Wang H-B Ghiran I Matthaei K Weller PF. Airway eosinophils: allergic inflammation recruited professional antigen-presenting cells. J Immunol (2007) 179(11): 7585– 92. 10.4049/jimmunol.179.11.7585 18025204 PMC2735454 · DOI
  90. [91]Shi HZ Humbles A Gerard C Jin Z Weller PF. Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest (2000) 105(7): 945– 53. 10.1172/JCI8945 10749574 PMC377484 · DOI
  91. [92]Del Pozo V De Andrés B Martín E Cárdaba B Fernández JC Gallardo S Eosinophil as antigen-presenting cell: activation of T cell clones and T cell hybridoma by eosinophils after antigen processing. Eur J Immunol (1992) 22(7): 1919– 25. 10.1002/eji.1830220736 1623930 · DOI
  92. [93]Padigel UM Lee JJ Nolan TJ Schad GA Abraham D. Eosinophils can function as antigen-presenting cells to induce primary and secondary immune responses to Strongyloides stercoralis. Infect Immun (2006) 74(6): 3232– 8. 10.1128/IAI.02067-05 16714550 PMC1479274 · DOI
  93. [94]Garro AP Chiapello LS Baronetti JL Masih DT. Rat eosinophils stimulate the expansion of Cryptococcus neoformans-specific CD4(+) and CD8(+) T cells with a T-helper 1 profile. Immunology (2011) 132(2): 174– 87. 10.1111/j.1365-2567.2010.03351.x 21039463 PMC3050441 · DOI
  94. [95]Jacobsen EA Zellner KR Colbert D Lee NA Lee JJ. Eosinophils regulate dendritic cells and Th2 pulmonary immune responses following allergen provocation. J Immunol (2011) 187: 6059– 68. 10.4049/jimmunol.1102299 22048766 PMC3375323 · DOI
  95. [96]Jacobsen EA Doyle AD Colbert DC Zellner KR Protheroe CA LeSuer WE Differential activation of airway eosinophils induces IL-13 mediated allergic Th2 pulmonary responses in mice. Allergy (2015) 70(9): 1148– 59. 10.1111/all.12655 26009788 PMC4552595 · DOI
  96. [97]Chu DK Jimenez-Saiz R Verschoor CP Walker TD Goncharova S Llop-Guevara A Indigenous enteric eosinophils control DCs to initiate a primary Th2 immune response in vivo. J Exp Med (2014) 211: 1657– 72. 10.1084/jem.20131800 25071163 PMC4113937 · DOI
  97. [98]Chu VT Fröhlich A Steinhauser G Scheel T Roch T Fillatreau S Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol (2011) 12: 151– 9. 10.1038/ni.1981 21217761 · DOI
  98. [99]Chu VT Beller A Rausch S Strandmark J Zänker M Arbach O Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity (2014) 40: 582– 93. 10.1016/j.immuni.2014.02.014 24745334 · DOI
  99. [100]Jung Y Wen T Mingler MK Caldwell JM Wang YH Chaplin DD IL-1β in eosinophil-mediated small intestinal homeostasis and IgA production. Mucosal Immunol (2015) 8(4): 930– 42. 10.1038/mi.2014.123 25563499 PMC4481137 · DOI
  100. [101]Todd R Donoff BR Chiang T Chou MY Elovic A Gallagher GT The eosinophil as a cellular source of transforming growth factor alpha in healing cutaneous wounds. Am J Pathol (1991) 138: 1307. 2053590 PMC1886395
  101. [102]Ohno I Nitta Y Yamauchi K Hoshi H Honma M Woolley K Eosinophils as a potential source of platelet-derived growth factor B-chain (PDGF-B) in nasal polyposis and bronchial asthma. Am J Respir Cell Mol Biol (1995) 13: 639– 47. 10.1165/ajrcmb.13.6.7576701 7576701 · DOI
  102. [103]Horiuchi T Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol (1997) 17: 70– 7. 10.1165/ajrcmb.17.1.2796 9224211 · DOI
  103. [104]Stenfeldt A-L Wennerås C. Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils. Immunology (2004) 112: 605– 14. 10.1111/j.1365-2567.2004.01906.x 15270732 PMC1782530 · DOI
  104. [105]Goh YPS Henderson NC Heredia JE Red Eagle A Odegaard JI Lehwald N Eosinophils secrete IL-4 to facilitate liver regeneration. Proc Natl Acad Sci U S A (2013) 110: 9914– 9. 10.1073/pnas.1304046110 23716700 PMC3683773 · DOI
  105. [106]Heredia JE Mukundan L Chen FM Mueller AA Deo RC Locksley RM Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell (2013) 153: 376– 88. 10.1016/j.cell.2013.02.053 23582327 PMC3663598 · DOI · Paper page
  106. [107]Kay AB The early history of the eosinophil. Clin Exp Allergy (2015) 45(3): 575– 82. 10.1111/cea.12480 25544991 · DOI
  107. [108]Aizawa H Zimmermann N Carrigan PE Lee JJ Rothenberg ME Bochner BS. Molecular analysis of human Siglec-8 orthologs relevant to mouse eosinophils: identification of mouse orthologs of Siglec-5 (mSiglec-F) and Siglec-10 (mSiglec-G). Genomics (2003) 82(5): 521– 30. 10.1016/S0888-7543(03)00171-X 14559209 · DOI
  108. [109]Ethier C Lacy P Davoine F. Identification of human eosinophils in whole blood by flow cytometry. Methods Mol Biol (2014) 1178: 81– 92. 10.1007/978-1-4939-1016-8_8 24986609 · DOI
  109. [110]Stevens WW Kim TS Pujanauski LM Hao X Braciale TJ. Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J Immunol Methods (2007) 327(1–2): 63– 74. 10.1016/j.jim.2007.07.011 17716680 PMC2670191 · DOI
  110. [111]Filley WV Ackerman SJ Gleich GJ An immunofluorescent method for specific staining of eosinophil granule major basic protein. J Immunol Methods (1981) 47(2): 227– 38. 10.1016/0022-1759(81)90123-X 7033389 · DOI
  111. [112]Melo RC Perez SA Spencer LA Dvorak AM Weller PF. Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils. Traffic (2005) 6(10): 866– 79. 10.1111/j.1600-0854.2005.00322.x 16138901 PMC2715425 · DOI
  112. [113]Kasperkiewicz M Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol (2007) 33: 67– 77. 10.1007/s12016-007-0030-y 18094948 · DOI
  113. [114]Jordon RE Beutner EH Witebsky E Blumental G Hale WL Lever WF Basement zone antibodies in bullous pemphigoid. JAMA (1967) 200: 751– 6. 10.1001/jama.200.9.751 4164640 · DOI
  114. [115]Stanley JR Hawley-Nelson P Yuspa SH Shevach EM Katz SI Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell (1981) 24: 897– 903. 10.1016/0092-8674(81)90115-X 7018697 · DOI
  115. [116]Mutasim DF Takahashi Y Labib RS Anhalt GJ Patel HP Diaz LA. A pool of bullous pemphigoid antigen(s) is intracellular and associated with the basal cell cytoskeleton-hemidesmosome complex. J Invest Dermatol (1985) 84: 47– 53. 10.1111/1523-1747.ep12274684 3880796 · DOI
  116. [117]Labib RS Anhalt GJ Patel HP Mutasim DF Diaz LA. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol (1986) 136: 1231– 5. 2418109
  117. [118]Kiss M Perényi A Marczinovits I Molnár J Dobozy A Kemény L Autoantibodies to human alpha6 integrin in patients with bullous pemphigoid. Ann N Y Acad Sci (2005) 1051: 104– 10. 10.1196/annals.1361.051 16126949 · DOI
  118. [119]Bekou V Thoma-Uszynski S Wendler O Uter W Schwietzke S Hunziker T Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA. J Invest Dermatol (2005) 124(4): 732– 40. 10.1111/j.0022-202X.2005.23646.x 15816831 · DOI
  119. [120]Borradori L Sonnenberg A. Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol (1999) 112: 411– 8. 10.1046/j.1523-1747.1999.00546.x 10201522 · DOI
  120. [121]Schmidt-Ullrich B Rule A Schaumburg-Lever G Leblanc C. Ultrastructural localization of in vivo-bound complement in bullous pemphigoid. J Invest Dermatol (1975) 65: 217– 9. 10.1111/1523-1747.ep12598218 50388 · DOI
  121. [122]Gammon WR Merritt CC Lewis DM Sams WM Jr Wheeler CE Jr Carlo J Leukocyte chemotaxis to the dermal-epidermal junction of human skin mediated by pemphigoid antibody and complement: mechanism of cell attachment in the in vitro leukocyte attachment method. J Invest Dermatol (1981) 76: 514– 22. 10.1111/1523-1747.ep12521246 7017015 · DOI
  122. [123]Liu Z Giudice GJ Swartz SJ Fairley JA Till GO Troy JL The role of complement in experimental bullous pemphigoid. J Clin Invest (1995) 95: 1539– 44. 10.1172/JCI117826 7706459 PMC295637 · DOI
  123. [124]Wintroub BU Mihm MC Jr Goetzl EJ Soter NA Austen KF. Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N Engl J Med (1978) 298: 417– 21. 10.1056/NEJM197802232980803 340950 · DOI
  124. [125]Dvorak AM Mihm MC Jr Osage JE Kwan TH Austen KF Wintroub BU. Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J Invest Dermatol (1982) 78: 91– 101. 10.1111/1523-1747.ep12505711 7035575 · DOI
  125. [126]Iryo K Tsuda S Sasai Y. Ultrastructural aspects of infiltrated eosinophils in bullous pemphigoid. J Dermatol (1992) 19: 393– 9. 10.1111/j.1346-8138.1992.tb03247.x 1401496 · DOI
  126. [127]Messingham KN Wang JW Holahan HM Srikantha R Aust SC Fairley JA Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid. Exp Dermatol (2016) 25(1): 50– 5. 10.1111/exd.12883 26475989 PMC4730885 · DOI
  127. [128]Bushkell LL Jordon RE. Bullous pemphigoid: a cause of peripheral blood eosinophilia. J Am Acad Dermatol (1983) 8: 648– 51. 10.1016/S0190-9622(83)70073-3 6345605 · DOI
  128. [129]Bernard P Venot J Constant F Bonnetblanc JM Blood eosinophilia as a severity marker for bullous pemphigoid. J Am Acad Dermatol (1987) 16: 879– 81. 10.1016/S0190-9622(87)80227-X 3553250 · DOI
  129. [130]Marzano AV Tedeschi A Fanoni D Bonanni E Venegoni L Berti E Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications. Br J Dermatol (2009) 160: 266– 72. 10.1111/j.1365-2133.2008.08880.x 18945300 · DOI
  130. [131]Yu KK Crew AB Messingham KAN Fairley JA Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol (2014) 71: 468– 74. 10.1016/j.jaad.2014.04.053 24954907 PMC9215508 · DOI
  131. [132]Tedeschi A Marzano AV Lorini M Balice Y Cugno M. Eosinophil cationic protein levels parallel coagulation activation in the blister fluid of patients with bullous pemphigoid. J Eur Acad Dermatol Venereol (2015) 29: 813– 7. 10.1111/jdv.12464 24650303 · DOI
  132. [133]Wakugawa M Nakamura K Hino H Toyama K Hattori N Okochi H Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol (2000) 143: 112– 6. 10.1046/j.1365-2133.2000.03599.x 10886144 · DOI
  133. [134]D’Auria L Pietravalle M Mastroianni A Ferraro C Mussi A Bonifati C IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity. Arch Dermatol Res (1998) 290: 25– 7. 10.1007/s004030050272 9522998 · DOI
  134. [135]Frezzolini A Teofoli P Cianchini G Barduagni S Ruffelli M Ferranti G Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid. Eur J Dermatol (2002) 12: 27– 31. 11809592
  135. [136]Engmann J Rüdrich U Behrens G Papakonstantinou E Gehring M Kapp A Increased activity and apoptosis of eosinophils in blister fluids, skin and peripheral blood of patients with bullous pemphigoid. Acta Derm Venereol (2017) 97(4): 464– 71. 10.2340/00015555-2581 27868136 · DOI
  136. [137]Borrego L Maynard B Peterson EA George T Iglesias L Peters MS Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am J Pathol (1996) 148: 897– 909. 8774144 PMC1861728
  137. [138]Ståhle-Bäckdahl M Inoue M Guidice GJ Parks WC. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest (1994) 93: 2022– 30. 10.1172/JCI117196 8182134 PMC294314 · DOI
  138. [139]Niimi Y Pawankar R Kawana S. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol (2006) 139: 104– 13. 10.1159/000090385 16374020 · DOI
  139. [140]Verraes S Hornebeck W Polette M Borradori L Bernard P Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol (2001) 117: 1091– 6. 10.1046/j.0022-202x.2001.01521.x 11710917 · DOI
  140. [141]Sitaru C Schmidt E Petermann S Munteanu LS Bröcker EB Zillikens D Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol (2002) 118: 664– 71. 10.1046/j.1523-1747.2002.01720.x 11918714 · DOI
  141. [142]Bernard P Aucouturier P Denis F Bonnetblanc J-M. Immunoblot analysis of IgG subclasses of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopathol (1990) 54: 484– 94. 10.1016/0090-1229(90)90060-4 1689231 · DOI
  142. [143]Döpp R Schmidt E Chimanovitch I Leverkus M Bröcker EB Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol (2000) 42: 577– 83. 10.1016/S0190-9622(00)90168-3 10727301 · DOI
  143. [144]Messingham KN Holahan HM Frydman AS Fullenkamp C Srikantha R Fairley JA Human eosinophils express the high affinity IgE receptor, FcεRI, in bullous pemphigoid. PLoS One (2014) 9: e107725 10.1371/journal.pone.0107725 25255430 PMC4177878 · DOI
  144. [145]Hofmann SC Technau K Müller AMS Lübbert M Bruckner-Tuderman L. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib. J Am Acad Dermatol (2007) 56: S68– 72. 10.1016/j.jaad.2006.02.059 17097375 · DOI
  145. [146]Liu Z Diaz LA Troy JL Taylor AF Emery DJ Fairley JA A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest (1993) 92(5): 2480– 8. 10.1172/JCI116856 7693763 PMC288433 · DOI
  146. [147]Hurskainen T Kokkonen N Sormunen R Jackow J Löffek S Soininen R Deletion of the major bullous pemphigoid epitope region of collagen XVII induces blistering, autoimmunization, and itching in mice. J Invest Dermatol (2015) 135: 1303– 10. 10.1038/jid.2014.443 25310407 · DOI
  147. [148]Snook J Are the inflammatory bowel diseases autoimmune disorders? Gut (1990) 31: 961– 3. 10.1136/gut.31.9.961 2210461 PMC1378647 · DOI
  148. [149]Das KM Biancone L Is IBD an autoimmune disorder? Inflamm Bowel Dis (2008) 14(Suppl 2): S97– 101. 10.1002/ibd.20723 18816728 · DOI
  149. [150]Truelove SC Richards WC Biopsy studies in ulcerative colitis. Br Med J (1956) 1: 1315– 8. 10.1136/bmj.1.4979.1315 13316140 PMC1980058 · DOI
  150. [151]Bercovitz ZT Sommers SC Altered inflammatory reaction in nonspecific ulcerative colitis. Arch Intern Med (1966) 117: 504– 10. 10.1001/archinte.117.4.504 5906642 · DOI
  151. [152]Rutgeerts P Geboes K Vantrappen G Kerremans R Coenegrachts JL Coremans G. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut (1984) 25: 665– 72. 10.1136/gut.25.6.665 6735250 PMC1432363 · DOI
  152. [153]Walsh RE Gaginella TS The eosinophil in inflammatory bowel disease. Scand J Gastroenterol (1991) 26: 1217– 24. 10.3109/00365529108998617 1763291 · DOI
  153. [154]Dubucquoi S Janin A Klein O Desreumaux P Quandalle P Cortot A Activated eosinophils and interleukin 5 expression in early recurrence of Crohn’s disease. Gut (1995) 37: 242– 6. 10.1136/gut.37.2.242 7557575 PMC1382725 · DOI
  154. [155]Makiyama K Kanzaki S Yamasaki K Zea-Iriarte W Tsuji Y. Activation of eosinophils in the pathophysiology of ulcerative colitis. J Gastroenterol (1995) 30(Suppl 8): 64– 9. 8563894
  155. [156]Saitoh O Kojima K Sugi K Matsuse R Uchida K Tabata K Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol (1999) 94: 3513– 20. 10.1111/j.1572-0241.1999.01640.x 10606313 · DOI
  156. [157]Jeziorska M Haboubi N Schofield P Woolley DE. Distribution and activation of eosinophils in inflammatory bowel disease using an improved immunohistochemical technique. J Pathol (2001) 194: 484– 92. 10.1002/path.904 11523058 · DOI
  157. [158]Coburn LA Horst SN Chaturvedi R Brown CT Allaman MM Scull BP High-throughput multi-analyte Luminex profiling implicates eotaxin-1 in ulcerative colitis. PLoS One (2013) 8: e82300. 10.1371/journal.pone.0082300 24367513 PMC3867379 · DOI
  158. [159]Zezos P Patsiaoura K Nakos A Mpoumponaris A Vassiliadis T Giouleme O Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy. Colorectal Dis (2014) 16: O420– 30. 10.1111/codi.12725 25040651 · DOI
  159. [160]Sadi G Yang Q Dufault B Stefanovici C Stoffman J El-Matary W. Prevalence of peripheral eosinophilia at diagnosis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2016) 62: 573– 6. 10.1097/MPG.0000000000000957 26308316 · DOI
  160. [161]Park S Abdi T Gentry M Laine L Histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol (2016) 111(12): 1692– 701. 10.1038/ajg.2016.418 27725645 · DOI
  161. [162]Vieira AT Fagundes CT Alessandri AL Castor MGM Guabiraba R Borges VO Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. Am J Pathol (2009) 175: 2382– 91. 10.2353/ajpath.2009.090093 19893035 PMC2789636 · DOI
  162. [163]Griseri T Arnold IC Pearson C Krausgruber T Schiering C Franchini F Granulocyte macrophage colony-stimulating factor-activated eosinophils promote interleukin-23 driven chronic colitis. Immunity (2015) 43: 187– 99. 10.1016/j.immuni.2015.07.008 26200014 PMC4518500 · DOI
  163. [164]Radnai B Sturm EM Stančić A Jandl K Labocha S Ferreirós N Eosinophils contribute to intestinal inflammation via chemoattractant receptor-homologous molecule expressed on Th2 cells, CRTH2, in experimental Crohn’s disease. J Crohns Colitis (2016) 10: 1087– 95. 10.1093/ecco-jcc/jjw061 26928963 PMC4892354 · DOI
  164. [165]Chen W Paulus B Shu D Wilson I Chadwick V. Increased serum levels of eotaxin in patients with inflammatory bowel disease. Scand J Gastroenterol (2001) 36: 515– 20. 10.1080/003655201750153377 11346206 · DOI
  165. [166]Mir A Minguez M Tatay J Pascual I Peña A Sanchiz V Elevated serum eotaxin levels in patients with inflammatory bowel disease. Am J Gastroenterol (2002) 97: 1452– 7. 10.1111/j.1572-0241.2002.05687.x 12094864 · DOI
  166. [167]Lampinen M Waddell A Ahrens R Carlson M Hogan SP. CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis. J Leukoc Biol (2013) 94: 1061– 70. 10.1189/jlb.1212640 23904440 PMC3800069 · DOI
  167. [168]Takahashi K Imaeda H Fujimoto T Ban H Bamba S Tsujikawa T Regulation of eotaxin-3/CCL26 expression by Th2 cytokines in human colonic myofibroblasts. Clin Exp Immunol (2013) 173(2): 323– 31. 10.1111/cei.12117 23607908 PMC3722932 · DOI
  168. [169]Park YR Choi SC Lee ST Kim KS Chae SC Chung HT. The association of eotaxin-2 and eotaxin-3 gene polymorphisms in a Korean population with ulcerative colitis. Exp Mol Med (2005) 37: 553– 8. 10.1038/emm.2005.68 16391516 · DOI
  169. [170]Forbes E Murase T Yang M Matthaei KI Lee JJ Lee NA Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase. J Immunol (2004) 172: 5664– 75. 10.4049/jimmunol.172.9.5664 15100311 · DOI
  170. [171]Waddell A Ahrens R Steinbrecher K Donovan B Rothenberg ME Munitz A Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2(+) inflammatory monocyte/macrophage-derived CCL11. J Immunol (2011) 186: 5993– 6003. 10.4049/jimmunol.1003844 21498668 PMC3423906 · DOI
  171. [172]Dvorak AM. Ultrastructural evidence for release of major basic protein-containing crystalline cores of eosinophil granules in vivo: cytotoxic potential in Crohn’s disease. J Immunol (1980) 125: 460– 2. 6155407
  172. [173]Nishitani H Okabayashi M Satomi M Shimoyama T Dohi Y. Infiltration of peroxidase-producing eosinophils into the lamina propria of patients with ulcerative colitis. J Gastroenterol (1998) 33: 189– 95. 10.1007/s005350050068 9605947 · DOI
  173. [174]Bischoff SC Mayer J Nguyen QT Stolte M Manns MP Immunnohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol (1999) 94: 3521– 9. 10.1111/j.1572-0241.1999.01641.x 10606314 · DOI
  174. [175]Carlson M Raab Y Peterson C Hällgren R Venge P. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol (1999) 94: 1876– 83. 10.1111/j.1572-0241.1999.01223.x 10406252 · DOI
  175. [176]Levy AM Gleich GJ Sandborn WJ Tremaine WJ Steiner BL Phillips SF. Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. Mayo Clin Proc (1997) 72: 117– 23. 10.4065/72.2.117 9033543 · DOI
  176. [177]Pronk-Admiraal CJ Linskens RK Van Bodegraven AA Tuynman HA Bartels PC. Serum eosinophil cationic protein in active and quiescent ulcerative colitis. Clin Chem Lab Med (2000) 38: 619– 22. 10.1515/CCLM.2000.090 11028767 · DOI
  177. [178]Wedrychowicz A Tomasik P Pieczarkowski S Kowalska-Duplaga K Grzenda-Adamek Z Fyderek K. Clinical value of serum eosinophilic cationic protein assessment in children with inflammatory bowel disease. Arch Med Sci (2014) 10: 1142– 6. 10.5114/aoms.2013.34415 25624851 PMC4296054 · DOI
  178. [179]Blom K Rubin J Halfvarson J Törkvist L Rönnblom A Sangfelt P Eosinophil associated genes in the inflammatory bowel disease 4 region: correlation to inflammatory bowel disease revealed. World J Gastroenterol (2012) 18: 6409– 19; discussion p. 6417–8. 10.3748/wjg.v18.i44.6409 23197886 PMC3508635 · DOI
  179. [180]Lampinen M Rönnblom A Amin K Kristjansson G Rorsman F Sangfelt P Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut (2005) 54: 1714– 20. 10.1136/gut.2005.066423 15886302 PMC1774808 · DOI
  180. [181]Furuta GT Nieuwenhuis EES Karhausen J Gleich G Blumberg RS Lee JJ Eosinophils alter colonic epithelial barrier function: role for major basic protein. Am J Physiol Gastrointest Liver Physiol (2005) 289: G890– 7. 10.1152/ajpgi.00015.2005 16227527 · DOI
  181. [182]Wallon C Persborn M Jönsson M Wang A Phan V Lampinen M Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis. Gastroenterology (2011) 140: 1597– 607. 10.1053/j.gastro.2011.01.042 21277851 · DOI
  182. [183]Wolk K Witte E Hoffmann U Doecke W-D Endesfelder S Asadullah K IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn’s disease. J Immunol (2007) 178: 5973– 81. 10.4049/jimmunol.178.9.5973 17442982 · DOI
  183. [184]Andoh A Zhang Z Inatomi O Fujino S Deguchi Y Araki Y Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology (2005) 129: 969– 84. 10.1053/j.gastro.2005.06.071 16143135 · DOI
  184. [185]Sugimoto K Ogawa A Mizoguchi E Shimomura Y Andoh A Bhan AK IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest (2008) 118: 534– 44. 10.1172/JCI33194 18172556 PMC2157567 · DOI
  185. [186]Sonnenberg GF Fouser LA Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol (2010) 107: 1– 29. 10.1016/B978-0-12-381300-8.00001-0 21034969 · DOI
  186. [187]Martin JC Bériou G Heslan M Bossard C Jarry A Abidi A IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis. Mucosal Immunol (2016) 9(2): 539– 49. 10.1038/mi.2015.83 26329427 · DOI
  187. [188]Owaga E Hsieh R-H Mugendi B Masuku S Shih C-K Chang J-S. Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases. Int J Mol Sci (2015) 16: 20841– 58. 10.3390/ijms160920841 26340622 PMC4613231 · DOI
  188. [189]Willebrand R Voehringer D. IL-33-induced cytokine secretion and survival of mouse eosinophils is promoted by autocrine GM-CSF. PLoS One (2016) 11: e0163751. 10.1371/journal.pone.0163751 27690378 PMC5045177 · DOI
  189. [190]Churg J Strauss L Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol (1951) 27: 277– 301. 14819261 PMC1937314
  190. [191]Lanham JG Elkon KB Pusey CD Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) (1984) 63: 65– 81. 10.1097/00005792-198403000-00001 6366453 · DOI
  191. [192]Khoury P Grayson PC Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol (2014) 10: 474– 83. 10.1038/nrrheum.2014.98 25003763 PMC4849122 · DOI
  192. [193]Greco A Rizzo MI De Virgilio A Gallo A Fusconi M Ruoppolo G Churg-Strauss syndrome. Autoimmun Rev (2015) 14: 341– 8. 10.1016/j.autrev.2014.12.004 25500434 · DOI
  193. [194]Mahr A Moosig F Neumann T Szczeklik W Taillé C Vaglio A Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol (2014) 26: 16– 23. 10.1097/BOR.0000000000000015 24257370 · DOI
  194. [195]Bonatti F Reina M Neri TM Martorana D. Genetic susceptibility to ANCA-associated vasculitis: state of the art. Front Immunol (2014) 5: 577. 10.3389/fimmu.2014.00577 25452756 PMC4233908 · DOI
  195. [196]Comarmond C Pagnoux C Khellaf M Cordier JF Hamidou M Viallard JF Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum (2013) 65(1): 270– 81. 10.1002/art.37721 23044708 · DOI
  196. [197]Moosig F Bremer JP Hellmich B Holle JU Holl-Ulrich K Laudien M A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis (2013) 72(6): 1011– 7. 10.1136/annrheumdis-2012-201531 22887848 · DOI · Paper page
  197. [198]Hellmich B Csernok E Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci (2005) 1051: 121– 31. 10.1196/annals.1361.053 16126951 · DOI
  198. [199]Jakiela B Sanak M Szczeklik W Sokolowska B Plutecka H Mastalerz L Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol (2011) 29: S23– 34. 21470488
  199. [200]Tsukadaira A Okubo Y Kitano K Horie S Momose T Takashi S Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. Allergy Asthma Proc (1999) 20: 39– 44. 10.2500/108854199778681486 10076708 · DOI
  200. [201]Kiene M Csernok E Müller A Metzler C Trabandt A Gross WL. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum (2001) 44: 469– 73. 10.1002/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0 11229479 · DOI

200 of 322 shown

Cited by

Sorted by citations

Authors
Diny, N. L., Rose, N. R., & Čiháková, D.
Affiliations
  • Johns Hopkins University (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Čiháková, Daniela
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2017-04-27
Volume
8
Pages
484-484
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2017.00484
PMC
PMC5406413
OpenAlex
W2609809651
Cited by
172
References
5
Citations by year
2026: 9 · 2025: 17 · 2024: 21 · 2023: 22 · 2022: 20 · 2021: 25 · 2020: 20 · 2019: 16 · 2018: 18 · 2017: 4
FWCI
1.95
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (R01HL113008, R01HL118183)
  • American Heart Association (15PRE25400010)
  • American Autoimmune Related Diseases Association
  • Johns Hopkins Bloomberg School of Public Health (Richard J and Margaret Conn Himelfarb Student Support)
Topics
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
  • Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
  • Health Sciences › Medicine › Surgery › Eosinophilic Esophagitis
Keywords
eosinophils, autoimmune disease, inflammatory bowel disease, neuromyelitis optica, bullous pemphigoid, autoimmune myocarditis, primary biliary cirrhosis, eosinophilic granulomatosis with polyangiitis, eosinophil-targeted therapy, eosinophil degranulation, antibody-dependent cellular cytotoxicity, proteolytic enzymes, cytokines, antigen presentation, eosinophilic esophagitis, hypereosinophilic syndrome, non-allergic asthma, eosinophilic disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review